GB2401547A — Particulate materials
Assigned to Nektar Therapeutics UK Ltd · Expires 2004-11-17 · 21y expired
What this patent protects
A particulate co-formulation, each particle comprising an intimate mixture of an active substance and an excipient, the particles having a volume mean diameter of 10 micrometers or less and have a finite gradient in the relative excipient concentration, which increases radially o…
USPTO Abstract
A particulate co-formulation, each particle comprising an intimate mixture of an active substance and an excipient, the particles having a volume mean diameter of 10 micrometers or less and have a finite gradient in the relative excipient concentration, which increases radially outwards of the core towards the surface of the particle, the rate of change in concentration being continuous rather than stepped. On oral administration the active ingredient is released at such a rate, the time taken (Tmax) to attain the maximum active concentration in the bloodstream is one hour or less. The co-formulation may be prepared using a Nektar (RTM) SCF particle formation process.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.